Search results for "66.70.+f"

showing 10 items of 80 documents

Cancer and Infective Endocarditis: Characteristics and Prognostic Impact

2021

Background: The interplay between cancer and IE has become of increasing interest. This study sought to assess the prevalence, baseline characteristics, management, and outcomes of IE cancer patients in the ESC EORP EURO-ENDO registry.Methods: Three thousand and eighty-five patients with IE were identified based on the ESC 2015 criteria. Three hundred and fifty-nine (11.6%) IE cancer patients were compared to 2,726 (88.4%) cancer-free IE patients.Results: In cancer patients, IE was mostly community-acquired (74.8%). The most frequently identified microorganisms were S. aureus (25.4%) and Enterococci (23.8%). The most frequent complications were acute renal failure (25.9%), embolic events (2…

medicine.medical_specialtyCardiovascular Medicineregistryvalve diseasesurgeryInternal medicinemedicinecancerDiseases of the circulatory (Cardiovascular) systemOriginal Researchbusiness.industryinfective endocarditisCancermedicine.diseaseCardiac surgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieBaseline characteristicsHeart failureInfective endocarditisRC666-701oncologyCohort[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieObservational studyCardiology and Cardiovascular MedicinebusinessValve diseasecardiac surgeryFrontiers in Cardiovascular Medicine
researchProduct

Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study)

2022

Abstract Aims The coronavirus disease‐2019 (COVID‐19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess the influence of COVID‐19 pandemic on hospital admissions and in‐hospital mortality rate in patients with acute heart failure (AHF) in a retrospective, multicentre study. Methods and results From 1 January 2019 to 31 December 2020, a total of 101 433 patients were hospitalized in 24 Cardiology Departments in Poland. The number of patients admitted due to AHF decreased by 23.4% from 9853 in 2019 to 7546 in 2020 (P < 0.001). We noted a significant reduction of self‐referrals in the times of COVID‐19 pandemic accounting 27.8% (P < 0.001), with increase…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Heart failureMedical careLevodopaCOVID‐19Internal medicinePandemicmedicineHumansDiseases of the circulatory (Cardiovascular) systemIn patientPandemicsRetrospective StudiesSARS-CoV-2business.industryMortality rateCarbidopaCOVID-19Original Articlesmedicine.diseaseIn‐hospital mortalityHospitalizationDrug CombinationsIn-hospital mortalityRC666-701Heart failureConcomitantAcute DiseaseOriginal ArticleCardiology and Cardiovascular MedicinebusinessHospital stayESC heart failure
researchProduct

Increased Phospholipid Transfer Protein Activity Is Associated With Markers of Enhanced Lipopolysaccharide Clearance in Human During Cardiopulmonary …

2021

Introduction: Lipopolysaccharide (LPS) is a component of gram-negative bacteria, known for its ability to trigger inflammation. The main pathway of LPS clearance is the reverse lipopolysaccharide transport (RLT), with phospholipid transfer protein (PLTP) and lipoproteins playing central roles in this process in experimental animal models. To date, the relevance of this pathway has never been studied in humans. Cardiac surgery with cardiopulmonary bypass is known to favor LPS digestive translocation. Our objective was to determine whether pre-operative PLTP activity and triglyceride or cholesterol-rich lipoprotein concentrations were associated to LPS concentrations in patients undergoing ca…

medicine.medical_specialtyLipopolysaccharideInflammationLipopolysaccharideCardiovascular Medicine030204 cardiovascular system & hematology[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyLipopolysaccharide transport03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinPhospholipid transfer proteinInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineLipoproteinOriginal Research030304 developmental biologyInflammation0303 health sciencesTriglyceridebusiness.industryCholesterolCardiopulmonary bypass[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyEndotoxemia3. Good healthEndocrinologychemistryRC666-701Phospholipid transfer protein (PLTP)lipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessLipoprotein
researchProduct

Depression mediates physical activity readiness and physical activity in patients with heart failure.

2021

Aims Although physical activity (PA) and exercise are essential for patients with heart failure (HF), adherence to the recommended guidelines is low. Not much is known about the mediating effect of HF patients mental state with their readiness for PA and reported activity levels. The purpose of this study is to investigate the mediatory effect of depression on PA readiness (physical limitation and psychological readiness) and self-reported PA in patients with HF. Methods and results In this cross-sectional study, 163 New York Heart Association Class I and II HF patients, during their clinic visit, reported on their physical limitation (PAR-Q) and psychological readiness [self-efficacy (ESES…

medicine.medical_specialtyPhysical activityDiseases of the circulatory (Cardiovascular) systemMedicineHumansIn patientSjukgymnastikPhysiotherapyExerciseDepression (differential diagnoses)Heart failure; Depression; Physical activity; Readiness; Motivation; Self-efficacyNew York Heart Association Class ISelf-efficacyHeart FailureMotivationbusiness.industryDepressionPhysical activityDepression Heart failure Motivation Physical activity Readiness Self-efficacyOriginal Articlesmedicine.diseaseReadinessPhysical limitationsCross-Sectional StudiesRC666-701Mental stateHeart failurePhysical therapyOriginal ArticleSelf ReportCardiology and Cardiovascular MedicinebusinessSelf‐efficacyESC heart failure
researchProduct

Acute kidney injury in heart failure: a population study

2020

Abstract Aims The objective of the present study is to assess the prognostic value of acute kidney injury (AKI) in the evolution of patients with heart failure (HF) using real‐world data. Methods and results Patients with a diagnosis of HF and with serial measurements of renal function collected throughout the study period were included. Estimated glomerular filtration rate (GFR) was calculated with the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration). AKI was defined when a sudden drop in creatinine with posterior recovery was recorded. According to the Risk, Injury, Failure, Loss, and End‐Stage Renal Disease (RIFLE) scale, AKI severity was graded in three categories: risk [1.5‐…

medicine.medical_specialtyRenal functionHeart failure030204 cardiovascular system & hematologyRisk of hospitalization03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOriginal Research ArticlesRisk of mortalitymedicineHumansDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleRetrospective StudiesFirst episodeCreatininebusiness.industryIncidence (epidemiology)Hazard ratioAcute kidney injurymedicine.disease3. Good healthAcute kidney injurychemistryRisk of mortalityCreatinineRC666-701CardiologyFemaleCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateRenal functionESC Heart Failure
researchProduct

Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.

2021

Aims: We sought to compare the effects of furosemide + hypertonic saline solution (HSS) treatment in patients with acute decompensated heart failure in comparison with furosemide alone and the response in a compensated state after an acute saline load with regard to serum levels of heart failure biomarkers. Methods and results: We enrolled 141 patients with acute decompensated heart failure with reduced ejection fraction admitted to our Internal Medicine ward from March 2017 to November 2019. A total of 73 patients were randomized to treatment with i.v. high-dose furosemide plus HSS, whereas 68 patients were randomized to i.v. high-dose furosemide alone. Patients treated with furosemide plu…

medicine.medical_specialtySettore MED/09 - Medicina InternaAcute decompensated heart failuremedicine.medical_treatmentfurosemide Heart failure HSS BiomarkersGastroenterologyFurosemideInternal medicineOriginal Research ArticlesmedicineDiseases of the circulatory (Cardiovascular) systemHumansOriginal Research ArticleHSSDiureticsSalineHeart FailureSaline Solution HypertonicEjection fractionTroponin Tbusiness.industryTherapeutic effectFurosemideAcute decompensated heart failuremedicine.diseaseHypertonic salineRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugESC heart failure
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Endovascular Treatment of Giant Visceral Aneurysms: An Overview

2021

Giant visceral aneurysms (or pseudoaneurysms) are aneurysmal lesions of the splanchnic vessels that are larger than 5 cm in diameter. As with other visceral aneurysms, treatment may be either surgical or endovascular. Both treatments face challenges given the anatomical complexity of such lesions. However, in the era of novel tools and techniques that have been developed in this field, an increasing number of giant visceral aneurysms can now be treated using endovascular approaches. The purpose of this article is to offer an overview of the most current techniques and trends in the endovascular treatment of giant visceral artery aneurysms.

medicine.medical_specialtybusiness.industry030204 cardiovascular system & hematology030218 nuclear medicine & medical imagingSurgery03 medical and health sciences0302 clinical medicineRC666-701medicinecardiovascular systemDiseases of the circulatory (Cardiovascular) systemSurgerycardiovascular diseasesEndovascular treatmentCardiology and Cardiovascular MedicinebusinessVascular and Endovascular Review
researchProduct

P10.08 THE BRACHIAL ARTERY ENDOTHELIAL FUNCTION UNDER THE INFLUENCE OF VASOACTIVE ANTIHYPERTENSIVE TREATMENT

2010

medicine.medical_specialtybusiness.industrySpecialties of internal medicineGeneral MedicineRC581-951Internal medicineVasoactivemedicine.arteryRC666-701CardiologymedicineDiseases of the circulatory (Cardiovascular) systemBrachial arterybusinessArtery Research
researchProduct

Plasma Testosterone Levels and Atherosclerotic Plaque Gene Expression in Men With Advanced Atherosclerosis

2021

Aims: Low plasma testosterone levels have been shown to predict worse outcome in men with severe atherosclerotic disease. We hypothesized that a low plasma testosterone level affects disease risk through changes in gene expression in atherosclerotic plaques. Therefore, we studied plasma testosterone levels in relation to gene expression levels in atherosclerotic plaque tissue of men with advanced atherosclerotic disease.Methods: Plasma testosterone levels were measured in 203 men undergoing carotid endarterectomy. The corresponding atherosclerotic plaque tissue was used for RNA sequencing. First, we assessed how often the androgen receptor gene was expressed in the plaque. Second, correlati…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmenttranscriptome (RNA-seq)menRNA-SeqEndogenyCarotid endarterectomyCardiovascular MedicineAndrogen receptorTranscriptomeEndocrinologyRC666-701Internal medicinetestosteroneGene expressionDiseases of the circulatory (Cardiovascular) systemMedicineatherosclerosisRNA-expressionCardiology and Cardiovascular MedicinebusinessGeneTestosteroneOriginal ResearchFrontiers in Cardiovascular Medicine
researchProduct